Case Report
Copyright ©The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Clin Cases. Jul 6, 2021; 9(19): 5280-5286
Published online Jul 6, 2021. doi: 10.12998/wjcc.v9.i19.5280
Infliximab treatment of glycogenosis Ib with Crohn's-like enterocolitis: A case report
You-Zhe Gong, Xue-Mei Zhong, Ji-Zhen Zou
You-Zhe Gong, Xue-Mei Zhong, Gastroenterology Department, Capital Institute of Pediatrics, Beijing 100020, China
Ji-Zhen Zou, Pathology Department, Capital Institute of Pediatrics, Beijing 100020, China
Author contributions: Gong YZ carried out the study, participated in collecting data, and drafted the manuscript; Zhong XM conceived the study and revised the paper; Zou JZ provided pathological data and revised the paper; All authors read and approved the final manuscript.
Supported by the Digestive Medical Coordinated Development Center of Beijing Hospitals Authority, No.XXZ0505.
Informed consent statement: Informed written consent was obtained from the patient for publication of this case report and accompanying images.
Conflict-of-interest statement: The authors declare that they have no competing interests.
CARE Checklist (2016) statement: The authors have read the CARE Checklist (2016), and the manuscript was prepared and revised according to the CARE Checklist.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Xue-Mei Zhong, MD, Associate Professor, Chief Doctor, Gastro-enterology Department, Capital Institute of Pediatrics, No. 2 Yabao Road, Chaoyang District, Beijing 100020, China. zhongxuemei@shouer.com.cn
Received: February 9, 2021
Peer-review started: February 9, 2021
First decision: February 28, 2021
Revised: March 11, 2021
Accepted: April 25, 2021
Article in press: April 25, 2021
Published online: July 6, 2021
Processing time: 134 Days and 21.3 Hours
Core Tip

Core Tip: Conventional treatment cannot alleviate symptoms of intestinal inflammation in glycogen storage disease type Ib (GSD-Ib). Although biological agents are effective for treating Crohn’s disease (CD), their application in the treatment of GSD-Ib with CD has been rarely reported. Infliximab was selected for this patient, and the intestinal symptoms were successfully alleviated. For cases with poor outcome using the granulocyte colony-stimulating factor treatment, infliximab can be used for therapy.